

SeneXta Therapeutics SA Announces The Successful Completion of Phase I Study with SNX-001

Lugano, Switzerland – 9th July, 2010 - SeneXta Therapeutics SA today announced the successful completion of a confirmatory Phase I study in healthy aged volunteers treated with its novel oral acetylcholinesterase (AChE) inhibitor SNX-001. The study was performed in Germany under an FDA and BfArM approved protocol. Results indicated that SNX-001 was well-tolerated and pharmacodynamically active at all dose levels.

The randomized, double-blind, placebo-controlled Phase I trial was designed as a single and multiple dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics of SNX-001. Safety and tolerability were determined by adverse events, clinical assessments, and laboratory studies. Twenty-four aged subjects received one of three different doses or placebo. The study measured levels of SNX-001 and levels of AChE inhibition in red blood cells. SNX-001 demonstrated dose-proportional pharmacokinetics and low inter-subject variability.

Ruggero Fariello, MD, FAAN, SeneXta's Chief Medical Advisor observed: "from my review of these rigorously collected data, these Phase I clinical results show that SNX-001 is well tolerated. More striking, pharmacodynamic proof of activity is achieved as subjects displayed a robust, sustained and dose-related reduction in AChE in red blood cells. This is a strong and reliable surrogate of a potentially useful clinical effect."

"Because of the unique, long-term effects of SNX-001, AChE inhibition in red blood cells can predict the progressive AChE inhibition in the patients' brain, a measure of the expected therapeutic effect of SNX-001 in the treatment of dementia" commented Donald Moss, PhD University of Texas El Paso Professor and SNX-001's Inventor.

Dr. Enrico Braglia, SeneXta's CEO concluded: "The Phase I data that we are announcing today are an important step in validating SeneXta's business model. We initiated our operations less than 18 months ago, and to date have completed a successful Phase I trial to support a Phase II study in patients with Alzheimer's disease. We also remain committed to developing SNX-001 for the treatment of dementia associated with stroke and finding new technologies to reach our targeted portfolio of three research programs."

Based on the success of the trial, SeneXta plans to proceed to a Phase II study to confirm the clinical benefit in a larger (~300 patients) and longer (6 months) trial.

About SNX-001

SNX-001 is a novel inhibitor of acetylcholinesterase (AChE) being investigated for the treatment of Alzheimer's disease. SNX-001 produces a selective, long-acting AChE inhibition, which may reduce the peripheral toxicity that limits the use of currently available short acting inhibitors. SNX-001 was not only designed to increase AChE inhibition in the brain above what can be achieved clinically at the present time with short-acting inhibitors, but the side-effect profile appears greatly improved, especially with regard to gastrointestinal effects.



About SenexTa Therapeutics SA

SenexTa is a privately held Swiss biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders including Alzheimer's disease, cognitive impairment secondary to ischemia, and other central nervous system (CNS) disorders. SenexTa was founded to acquire intellectual properties for the treatment of CNS disorders. The Company has already recruited a world-leading team of CNS experts and established solid collaborations with U.S. and European Union universities.

For more information:

SENEXTA THERAPEUTICS SA

Via Cantonale 1
6900 Lugano
[Switzerland](#)

info@senexta.com